A pharmaceutical composition for treating anxiety disorder due to stroke containing sildenafil and Rho-associasted kinase inhibitor

摘要

The present invention relates to a pharmaceutical composition for the treatment of sequelae due to ischemic cerebrovascular disease, comprising a phosphodiesterase type 5 activity inhibitor (phosphodiesterase type 5 inhibitor) and a ROCK inhibitor (Rho-associasted kinase inhibitor), and more specifically It relates to a pharmaceutical composition for treating anxiety disorder due to stroke, comprising sildenafil and GSK429286A. The present inventors studied to use sildenafil and a ROCK inhibitor in combination in the treatment of sequelae due to stroke based on clinical knowledge related to stroke treatment.As a result, when sildenafil and a ROCK inhibitor were administered in combination compared to the case where a ROCK inhibitor was administered alone. It was confirmed for the first time that anxiety disorders due to stroke are significantly improved, and the pharmaceutical composition according to the present invention is expected to be usefully used in the treatment or research of sequelae related to anxiety caused by stroke.